2260696-63-5

Product Details:

CasNo： 2260696-63-5

Molecular Formula： C20H11F6N3O2

Appearance： Off-white to pale yellow powder

Delivery Time： 2 weeks after order

Packing： Aluminium bag

Purity： 99%

1. Product Overview

JXL‑069 (also referred to as PP405 in clinical development) is a first‑in‑class, potent, and selective small‑molecule inhibitor of the mitochondrial pyruvate carrier (MPC). It was originally discovered at the University of California, Los Angeles (UCLA) and licensed to Pelage Pharmaceuticals for clinical development. The compound is being advanced as a topical treatment for androgenetic alopecia (AGA, pattern hair loss) with a novel mechanism of action distinct from existing therapies.

2. Mechanism of Action

PP405/JXL‑069 acts by specifically inhibiting MPC1 and MPC2, blocking pyruvate import into mitochondria. This inhibition:

• Causes pyruvate accumulation in the cytoplasm
• Stimulates lactate dehydrogenase (LDH) activity in hair follicle stem cells (HFSCs)
• Shifts cellular metabolism toward glycolysis, increasing intracellular lactate levels
• Activates dormant HFSCs and re‑initiates the hair growth cycle (anagen phase)

This metabolic reprogramming provides the energy required for HFSC proliferation and hair follicle regeneration.

3. Clinical Development Status

• Phase IIa Clinical Trial: Completed in 78 male and female AGA patients (randomized, double‑blind, placebo‑controlled)
• Dosing: 0.05% topical gel applied once daily to the scalp
• Key Efficacy Results:
  • At Week 4: 31% of PP405‑treated subjects achieved ≥20% increase in hair density (p<0.001 vs. placebo)
  • At Week 8: Efficacy was sustained, with 0% response in the placebo group
• Safety Profile:
  • No detectable systemic absorption in blood samples
  • Well‑tolerated with minimal local adverse events (e.g., mild scalp irritation)

4. Key Advantages

• Novel Target: First MPC inhibitor in clinical development for hair loss
• Local Action: Topical formulation with no systemic exposure, minimizing safety risks
• Rapid Onset: Significant hair growth observed as early as 4 weeks of treatment
• Broad Potential: May benefit both men and women with AGA

5. Applications

• Primary: Topical treatment for androgenetic alopecia (male/female pattern baldness)
• Research Use: Chemical probe for studying mitochondrial metabolism, glycolysis, and stem cell activation

6. Storage & Handling

• Store at ‑20°C (desiccated, protected from light)
• For research use only (not for human or veterinary use)